Evotec SE (EVOTF) Financials

EVOTF Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 1.9 billion 1.1 billion
Dec. 31, 2025 2.1 billion 1.1 billion
Sept. 30, 2025 2.1 billion 1.1 billion
June 30, 2025 2.1 billion 1.1 billion

EVOTF Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -7.3 million ?
Dec. 31, 2025 57.5 million ?
Sept. 30, 2025 -103.0 million ?
June 30, 2025 3.2 million ?

EVOTF Net Income

No data available :(

EVOTF Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 511.6 million 343.8 million -
Dec. 31, 2025 559.1 million 228.7 million 175.0 million
Sept. 30, 2025 278.4 million 455.0 million -
June 30, 2025 420.1 million - -

EVOTF Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 203.5 million
Dec. 31, 2025 208.3 million
Sept. 30, 2025 208.5 million
June 30, 2025 209.3 million

EVOTF Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 4.8 million 11.6 million 50.4 million -
Dec. 31, 2025 17.2 million 11.5 million 52.0 million -
Sept. 30, 2025 23.7 million 10.2 million 49.7 million -
June 30, 2025 28.1 million 9.7 million 49.0 million -

EVOTF Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 180.2 million 182.0 million
Dec. 31, 2025 297.2 million 205.1 million
Sept. 30, 2025 192.3 million 192.4 million
June 30, 2025 201.8 million 191.7 million

EVOTF

Price: $6.69

52 week price:
4.73
8.58

Earnings Per Share: -1.28 USD

Exchange: PNK

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Market Capitalization: 1.2 billion

Links: